Evidence map›Paper›PMID 33199443›Full record

Trial reportGut2021

EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.

Elizabeth C Smyth, Georgios Vlachogiannis, Somaieh Hedayat, Alice Harbery, Sanna Hulkki-Wilson, Massimiliano Salati, Kyriakos Kouvelakis, Javier Fernandez-Mateos, George D Cresswell, Elisa Fontana and 23 more

Open access · hybridAbstract readClinical Trial, Phase IIIComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Gut, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Gastric cancer and genomics: review of literature.Journal of gastroenterology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 10 institutions in 3 countries.

Elizabeth C Smyth *Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Georgios Vlachogiannis *Molecular Pathology, The Institute of Cancer Research, Sutton, UK.ORCID 0000-0003-3114-8772
Somaieh HedayatMolecular Pathology, The Institute of Cancer Research, Sutton, UK.
Alice HarberyCancer Therapeutics, The Institute of Cancer Research, Sutton, UK.
Sanna Hulkki-WilsonMolecular Pathology, The Institute of Cancer Research, Sutton, UK.
Massimiliano SalatiMolecular Pathology, The Institute of Cancer Research, Sutton, UK.
Kyriakos KouvelakisClinical Research & Development, Royal Marsden Hospital NHS Trust, London, UK.
Javier Fernandez-MateosCentre for Evolution and Cancer, The Institute of Cancer Research, Sutton, UK.
George D CresswellCentre for Evolution and Cancer, The Institute of Cancer Research, Sutton, UK.ORCID 0000-0003-3303-068X
Elisa FontanaMolecular Pathology, The Institute of Cancer Research, Sutton, UK.
Therese SeidlitzDepartment of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Dresden, Germany.
Clare PeckittClinical Research & Development, Royal Marsden Hospital NHS Trust, London, UK.
Jens C HahneMolecular Pathology, The Institute of Cancer Research, Sutton, UK.
Andrea LampisMolecular Pathology, The Institute of Cancer Research, Sutton, UK.
Ruwaida BegumDepartment of Medicine, Royal Marsden Hospital NHS Trust, London, UK.
David WatkinsDepartment of Medicine, Royal Marsden Hospital NHS Trust, London, UK.
Sheela RaoDepartment of Medicine, Royal Marsden Hospital NHS Trust, London, UK.
Naureen StarlingDepartment of Medicine, Royal Marsden Hospital NHS Trust, London, UK.
Tom WaddellDepartment of Medicine, Royal Marsden Hospital NHS Trust, London, UK.
Alicia OkinesDepartment of Medicine, Royal Marsden Hospital NHS Trust, London, UK.
Tom CrosbyDepartment of Clinical Oncology, Velindre Cancer Centre, Cardiff, UK.
Was MansoorDepartment of Medical Oncology, Christie Hospital, Manchester, UK.
Jonathan WadsleyCancer Clinical Trials Centre, Weston Park Cancer Centre, Sheffield, UK.
Gary MiddletonInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Matteo FassanDepartment of Medicine (DIMED), University of Padua, Padova, Italy.
Andrew WotherspoonHistopathology, Royal Marsden Hospital NHS Trust, London, UK.
Chiara BraconiDepartment of Medicine, Royal Marsden Hospital NHS Trust, London, UK.
Ian ChauDepartment of Medicine, Royal Marsden Hospital NHS Trust, London, UK.
Igor VivancoCancer Therapeutics, The Institute of Cancer Research, Sutton, UK.
Andrea SottorivaCentre for Evolution and Cancer, The Institute of Cancer Research, Sutton, UK.
Daniel E StangeDepartment of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Dresden, Germany.ORCID 0000-0003-4246-2230
David Cunningham *Department of Medicine, Royal Marsden Hospital NHS Trust, London, UK.
Nicola Valeri *Department of Medicine, Royal Marsden Hospital NHS Trust, London, UK nicola.valeri@icr.ac.uk.ORCID 0000-0002-5426-5683
Institute of Cancer Research · GBRoyal Marsden Hospital · GBCambridge University Hospitals NHS Foundation Trust · GBGerman Cancer Research Center · DEThe Christie Hospital · GBUniversity Hospital Carl Gustav Carus · DEUniversity of Birmingham · GBUniversity of Padua · ITVelindre Cancer Centre · GBWeston Park Cancer Centre · GB

Funding

The Role of the Microbiome in Cancer Suppression and Susceptibility Across SpeciesU54CA217376 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI MALEY, CARLO · 2018 to 2022
$8.6M
Cancer Research UK 18052Cancer Research UK A18052Cancer Research UK A22909NCI NIH HHS U54 CA217376Wellcome Trust
6 · The paper itself

Abstract

objectiveEpidermal growth factor receptor (EGFR) inhibition may be effective in biomarker-selected populations of advanced gastro-oesophageal adenocarcinoma (aGEA) patients. Here, we tested the association between outcome and

design

results

conclusion

Indexed as

AdenocarcinomaAgedAntibiotics, AntineoplasticAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorEpirubicinErbB ReceptorsEsophageal NeoplasmsHumansMaleMiddle AgedPanitumumabStomach NeoplasmsAntibiotics, AntineoplasticAntineoplastic Agents, ImmunologicalBiomarkers, TumorEpirubicinErbB ReceptorsPanitumumabgastric adenocarcinomagastrointestinal cancermolecular oncologyoesophageal cancer

Identifiers

PMID33199443
PMCPMC8355876
OpenAlexW3101423836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.